lifestyle.newsblaze.com

Author: RenovoRx, Inc.

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

April 14, 2026
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

April 8, 2026
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

April 1, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

March 30, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

March 26, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

March 23, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

March 20, 2026
RenovoRx Announces $10 Million at Market Private Placement

March 18, 2026
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

February 27, 2026
RenovoRx Establishes RenovoCath® Medical Advisory Board

February 12, 2026